Ibopamine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Mild heart failure 100-200 mg 2-3 times/day. Ophth Mydriasis As 2% soln: Instill as directed.
Dosage Details
Ophthalmic
Mydriasis
Adult: As hydrochloride: Instil in the eye as 2% eye drops.

Oral
Mild heart failure
Adult: 100-200 mg bid-tid.
Contraindications
Oral: Severe heart failure, phaeochromocytoma. Ophthalmic: Angle-closure glaucoma.
Special Precautions
CV diseases; hyperthyroidism; DM; elderly; pregnancy, lactation; prostate disorders; occlusive vascular disease; cardiac arrhythmias.
Adverse Reactions
Palpitations, tachycardia, arrhythmias, reflex bradycardia. Hypotension, dizziness, fainting. Anxiety, fear, restlessness, insomnia, confusion, irritability, headache, psychotic symptoms. Dyspnoea, weakness, anorexia, nausea, vomiting. Mydriasis, difficulty in micturition and urinary retention, piloerection, sweating, increased salivation. Hyperglycaemia. Hypokalaemia and muscle tremor.
Drug Interactions
Increased cardiac effects with volatile anaesthetics, thyroid hormones, cardiac glycosides and antiarrhythmics. Additive hypotensive effects with antihypertensives. Severe hypotension may occur with guanethidine. Increased risk of hypotension and tachycardia with α-blockers. Increased risk of hypertension with nonselective β-beta blockers. Increased risk of hypertension and arrhythmias with TCAs. Additive CV toxicity with levodopa, bromocriptine.
Potentially Fatal: Increased risk of mortality with amiodarone (although interaction is not established).
Action
Description: Ibopamine is a peripheral dopamine agonist with vasodilating properties and a weak positive inotropic effect. It stimulates α- and β-adrenoceptors at high concentrations.
Pharmacokinetics:
Absorption: Peak plasma concentrations after 30 min (oral).
Metabolism: Rapidly converted to epinene (active metabolite) by esterase hydrolysis.
Disclaimer: This information is independently developed by MIMS based on Ibopamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in